1, early stage (Ⅰ, Ⅱ): surgery is the main treatment, for patients with serious medical comorbidities; advanced age; patients who refuse surgery can be preferred to radical radiation therapy. In principle, the irradiation dose should not be less than 60Gy. 2, locally advanced stage IIIa (T1-3N2M0, T3-4N1M0) and IIIb (T1-3N3M0, T4N2M0 and T4N3): (1) Treatment of stage IIIa, concurrent radiotherapy is recommended, and some of those who can be operated after treatment can choose the integrated treatment of surgery, radiotherapy and chemotherapy. (2) For stage IIIb treatment, concurrent radiotherapy is the standard treatment. Sequential radiotherapy and chemotherapy can also be chosen according to the patient’s specific conditions, but radiation therapy should be given as early as possible. (3) In advanced stage (stage IV) patients, chemotherapy is the main treatment combined with local radiotherapy, but the benefit of treatment should be considered first? 4.For those with EGFR mutation in lung adenocarcinoma or beneficial to treatment, conditions allow to combine or apply biological targeting drugs such as gefitinib or erlotinib alone. 5.Stage IV patients with isolated metastasis should pay attention to local treatment and should be given adequate radiotherapy or surgical resection in order to achieve long-term survival for some patients. 6. All treatments should be individualized and comprehensive under the principles of evidence-based medicine. Any treatment should not be at the expense of the body.